Dystrophin and mutations: One gene, several proteins, multiple phenotypes

Lancet Neurology

Volumn 2, Issue 12, 2003, Pages 731-740

  Muntoni, Francesco ^a   Torelli, Silvia ^a   Ferlini, Alessandra ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; ISOPROTEIN;

CENTRAL NERVOUS SYSTEM; DISEASE SEVERITY; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENE DUPLICATION; GENE FUNCTION; GENE MUTATION; GENOTYPE; HEART DILATATION; HUMAN; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RETINA; REVIEW; X CHROMOSOME LINKAGE;

EID: 0344420060     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00585-4     Document Type: Review

References (149)

1. Kunkel L.M., Beggs A.H., Hoffman E.P. Molecular genetics of Duchenne and Becker muscular dystrophy: emphasis on improved diagnosis. Clin Chem. 35:(suppl 7):1989;B21-B24.
2. Mandel J.L. Dystrophin: the gene and its product. Nature. 339:1989;584-586.
3. Manole E. The dystrophin gene and its product: a view. Rom J Neurol Psychiatry. 33:1995;109-119.
4. Lambert M., Chafey P., Hugnot J.P., et al. Expression of the transcripts initiated in the 62nd intron of the dystrophin gene. Neuromuscul Disord. 3:1993;519-524.
5. Sironi M., Bardoni A., Felisari G., et al. Transcriptional activation of the non-muscle, full-length dystrophin isoforms in Duchenne muscular dystrophy skeletal muscle. J Neurol Sci. 186:2001;51-57.
6. Torelli S., Ferlini A., Obici L., Sewry C., Muntoni F. Expression, regulation and localisation of dystrophin isoforms in human foetal skeletal and cardiac muscle. Neuromuscul Disord. 9:1999;541-551.
7. Bies R.D., Friedman D., Roberts R., Perryman M.B., Caskey C.T. Expression and localization of dystrophin in human cardiac Purkinje fibers. Circulation. 86:1992;147-153.
8. Bies R.D., Phelps S.F., Cortez M.D., Roberts R., Caskey C.T., Chamberlain J.S. Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. Nucleic Acids Res. 20:1992;1725-1731.
9. Nudel U., Zuk D., Einat P., et al. Duchenne muscular dystrophy gene product is not identical in muscle and brain. Nature. 337:1989;76-78.
10. Gorecki D.C., Monaco A.P., Derry J.M., Walker A.P., Barnard E.A., Barnard P.J. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet. 1:1992;505-510.
11. Muntoni F., Melis M.A., Ganau A., Dubowitz V. Transcription of the dystrophin gene in normal tissues and in skeletal muscle of a family with X-linked dilated cardiomyopathy. Am J Hum Genet. 56:1995;151-157.
12. Yaffe D., Makover A., Lederfein D., et al. Multiple products of the Duchenne muscular dystrophy gene. Symp Soc Exp Biol. 46:1992;179-188.
13. Nishio H., Takeshima Y., Narita N., et al. Identification of a novel first exon in the human dystrophin gene and of a new promoter located more than 500 kb upstream of the nearest known promoter. J Clin Invest. 94:1994;1037-1042.
14. Wheway J.M., Roberts R.G. The dystrophin lymphocyte promoter revisited: 4.5 megabase intron, or artifact? Neuromuscul Disord. 13:2003;17-20.
15. Sadoulet-Puccio H.M., Kunkel L.M. Dystrophin and its isoforms. Brain Pathol. 6:1996;25-35.
16. Surono A., Takeshima Y., Wibawa T., Ikezawa M., Nonaka I., Matsuo M. Circular dystrophin RNAs consisting of exons that were skipped by alternative splicing. Hum Mol Genet. 8:1999;493-500.
17. Roberts RG. Dystrophins and dystrobrevins. Genome Biol 2001; 2: REVIEWS3006.
18. Cohn R.D., Campbell K.P. Molecular basis of muscular dystrophies. Muscle Nerve. 23:2000;1456-1471.
19. Straub V., Campbell K.P. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol. 10:1997;168-175.
20. Davies K.E., Tinsley J.M., Blake D.J. Molecular analysis of Duchenne muscular dystrophy: past, present, and future. Ann N Y Acad Sci. 758:1995;287-296.
21. Tinsley J.M., Blake D.J., Pearce M., Knight A.E., Kendrick-Jones J., Davies K.E. Dystrophin and related proteins. Curr Opin Genet Dev. 3:1993;484-490.
22. Love D.R., Byth B.C., Tinsley J.M., Blake D.J., Davies K.E. Dystrophin and dystrophin-related proteins: a review of protein and RNA studies. Neuromuscul Disord. 3:1993;5-21.
23. Rando T.A. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24:2001;1575-1594.
24. Campbell K.P., Kahl S.D. Association of dystrophin and an integral membrane glycoprotein. Nature. 338:1989;259-262.
25. Hoffman E.P., Dressman D. Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends Pharmacol Sci. 22:2001;465-470.
26. Culligan K.G., Mackey A.J., Finn D.M., Maguire P.B., Ohlendieck K. Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Int J Mol Med. 2:1998;639-648.
27. Michalak M., Opas M. Functions of dystrophin and dystrophin associated proteins. Curr Opin Neurol. 10:1997;436-442.
28. Emery A.E. The muscular dystrophies. Lancet. 359:2002;687-695.
29. Bushby K.M. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. Hum Mol Genet. 8:1999;1875-1882.
30. Petrof B.J. Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am J Phys Med Rehabil. 81:(suppl 11):2002;S162-S174.
31. Ilsley J.L., Sudol M., Winder S.J. The interaction of dystrophin with beta-dystroglycan is regulated by tyrosine phosphorylation. Cell Signal. 13:2001;625-632.
32. Madhavan R., Jarrett H.W. Calmodulin-activated phosphorylation of dystrophin. Biochemistry. 33:1994;5797-5804.
33. Pillers D.M., Bulman D.E., Weleber R.G., et al. Dystrophin expression in the human retina is required for normal function as defined by electroretinography. Nat Genet. 4:1993;82-86.
34. D'Souza V.N., Nguyen T.M., Morris G.E., Karges W., Pillers D.A., Ray P.N. A novel dystrophin isoform is required for normal retinal electrophysiology. Hum Mol Genet. 4:1995;837-842.
35. Lidov H.G., Selig S., Kunkel L.M. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum Mol Genet. 4:1995;329-335.
36. Byers T.J., Lidov H.G., Kunkel L.M. An alternative dystrophin transcript specific to peripheral nerve. Nat Genet. 4:1993;77-81.
37. Bar S., Barnea E., Levy Z., Neuman S., Yaffe D., Nudel U. A novel product of the Duchenne muscular dystrophy gene which greatly differs from the known isoforms in its structure and tissue distribution. Biochem J. 272:1990;557-560.
38. Austin R.C., Howard P.L., D'Souza V.N., Klamut H.J., Ray P.N. Cloning and characterization of alternatively spliced isoforms of Dp71. Hum Mol Genet. 4:1995;1475-1483.
39. Den Dunnen J.T., Grootscholten P.M., Bakker E., et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet. 45:1989;835-847.
40. Beggs A.H., Koenig M., Boyce F.M., Kunkel L.M. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet. 86:1990;45-48.
41. Oudet C., Hanauer A., Clemens P., Caskey T., Mandel J.L. Two hot spots of recombination in the DMD gene correlate with the deletion prone regions. Hum Mol Genet. 1:1992;599-603.
42. Nobile C., Galvagni F., Marchi J., Roberts R., Vitiello L. Genomic organization of the human dystrophin gene across the major deletion hot spot and the 39 region. Genomics. 28:1995;97-100.
43. Abbs S., Bobrow M. Analysis of quantitative PCR for the diagnosis of deletion and duplication carriers in the dystrophin gene. J Med Genet. 29:1992;191-196.
44. Yau S.C., Bobrow M., Mathew C.G., Abbs S.J. Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. J Med Genet. 33:1996;550-558.
45. White S., Kalf M., Liu Q., et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet. 71:2002;365-374.
46. Love D.R., Flint T.J., Genet S.A., Middleton-Price H.R., Davies K.E. Becker muscular dystrophy patient with a large intragenic dystrophin deletion: implications for functional minigenes and gene therapy. J Med Genet. 28:1991;860-864.
47. England S.B., Nicholson L.V., Johnson M.A., et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 343:1990;180-182.
48. Love D.R., Flint T.J., Marsden R.F., et al. Characterization of deletions in the dystrophin gene giving mild phenotypes. Am J Med Genet. 37:1990;136-142.
49. Angelini C., Fanin M., Freda M.P., et al. Prognostic factors in mild dystrophinopathies. J Neurol Sci. 142:1996;70-78.
50. Beggs A.H., Hoffman E.P., Snyder J.R., et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet. 49:1991;54-67.
51. Gospe S.M. Jr, Lazaro R.P., Lava N.S., Grootscholten P.M., Scott M.O., Fischbeck K.H. Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene. Neurology. 39:1989;1277-1280.
52. Melis M.A., Cau M., Muntoni F., et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol. 2:1998;255-261.
53. Monaco A.P., Bertelson C.J., Liechti-Gallati S., Moser H., Kunkel L.M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 2:(1):1988;90-95.
54. Kerr T.P., Sewry C.A., Robb S.A., Roberts R.G. Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay? Hum Genet. 109:2001;402-407.
55. Koenig M., Beggs A.H., Moyer M., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 45:1989;498-506.
56. Nicholson L.V., Johnson M.A., Davies K.E. Integrated dystrophin analysis using immunocytochemical, biochemical and genetic techniques. Basic Appl Histochem. 34:1990;169-175.
57. Malhotra S.B., Hart K.A., Klamut H.J., et al. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science. 242:1988;755-759.
58. Baumbach L.L., Chamberlain J.S., Ward P.A., Farwell N.J., Caskey C.T. Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology. 39:1989;465-474.
59. Gillard E.F., Chamberlain J.S., Murphy E.G., et al. Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. Am J Hum Genet. 45:1989;507-520.
60. Muntoni F., Gobbi P., Sewry C., et al. Deletions in the 5′ region of dystrophin and resulting phenotypes. J Med Genet. 31:1994;843-847.
61. Arahata K., Beggs A.H., Honda H., et al. Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy. J Neurol Sci. 101:1991;148-156.
62. Nicholson L.V., Bushby K.M., Johnson M.A., den Dunnen J.T., Ginjaar I.B., van Ommen G.J. Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame. J Med Genet. 29:1992;892-896.
63. Patria S.Y., Alimsardjono H., Nishio H., Takeshima Y., Nakamura H., Matsuo M. A case of Becker muscular dystrophy resulting from the skipping of four contiguous exons (71-74) of the dystrophin gene during mRNA maturation. Proc Assoc Am Physicians. 108:1996;308-314.
64. Winnard A.V., Mendell J.R., Prior T.W., Florence J., Burghes A.H. Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. Am J Hum Genet. 56:1995;158-166.
65. Sherratt T.G., Vulliamy T., Dubowitz V., Sewry C.A., Strong P.N. Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet. 53:1993;1007-1015.
66. Prior T.W., Bartolo C., Papp A.C., et al. Dystrophin expression in a Duchenne muscular dystrophy patient with a frame shift deletion. Neurology. 48:1997;486-488.
67. Love D.R., England S.B., Speer A., et al. Sequences of junction fragments in the deletion-prone region of the dystrophin gene. Genomics. 10:1991;57-67.
68. Blonden L.A., Grootscholten P.M., den Dunnen J.T., et al. 242 breakpoints in the 200-kb deletion-prone P20 region of the DMD gene are widely spread. Genomics. 10:1991;631-639.
69. Pizzuti A., Pieretti M., Fenwick R.G., Gibbs R.A., Caskey C.T. A transposon-like element in the deletion-prone region of the dystrophin gene. Genomics. 13:1992;594-600.
70. Brown J., Dry K.L., Edgar A.J., et al. Analysis of three deletion breakpoints in Xp21.1 and the further localization of RP3. Genomics. 37:1996;200-210.
71. Suminaga R., Takeshima Y., Yasuda K., Shiga N., Nakamura H., Matsuo M. Non-homologous recombination between Alu and LINE-1 repeats caused a 430-kb deletion in the dystrophin gene: a novel source of genomic instability. J Hum Genet. 45:2000;331-336.
72. Nobile C., Toffolatti L., Rizzi F., et al. Analysis of 22 deletion breakpoints in dystrophin intron 49. Hum Genet. 110:2002;418-421.
73. Toffolatti L., Cardazzo B., Nobile C., et al. Investigating the mechanism of chromosomal deletion: characterization of 39 deletion breakpoints in introns 47 and 48 of the human dystrophin gene. Genomics. 80:2002;523-530.
74. Sironi M., Pozzoli U., Cagliani R., et al. Relevance of sequence and structure elements for deletion events in the dystrophin gene major hot-spot. Hum Genet. 112:2003;272-288.
75. Gualandi F., Rimessi P., Cardazzo B., et al. Genomic definition of a pure intronic dystrophin deletion responsible for an XLDC splicing mutation: in vitro mimicking and antisense modulation of the splicing abnormality. Gene. 311:2003;25-33.
76. Gualandi F. T.C., Rimessi P., Calzolari E., et al. Multiple exon skipping and RNA circularisation contribute to the severe phenotypic expression of exon 5 dystrophin deletion. J Med Genet. 40:2003;100.
77. Wilton S.D., Dye D.E., Laing N.G. Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve. 20:1997;728-734.
78. Lu Q.L., Morris G.E., Wilton S.D., et al. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol. 148:2000;985-996.
79. Sironi M., Cagliani R., Comi G.P., et al. Trans-acting factors may cause dystrophin splicing misregulation in BMD skeletal muscles. FEBS Lett. 537:2003;30-34.
80. Wilton S.D., Lloyd F., Carville K., et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord. 9:1999;330-338.
81. Mann C.J., Honeyman K., Cheng A.J., et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA. 98:2001;42-47.
82. van Deutekom J.C., Bremmer-Bout M., Janson A.A., et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 10:2001;1547-1554.
83. De Angelis F.G., Sthandier O., Berarducci B., et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc Natl Acad Sci USA. 99:2002;9456-9461.
84. Mann C.J., Honeyman K., McClorey G., Fletcher S., Wilton S.D. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med. 4:2002;644-654.
85. Aartsma-Rus A., Bremmer-Bout M., Janson A.A., den Dunnen J.T., van Ommen G.J., van Deutekom J.C. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 12:(suppl 1):2002;S71-S77.
86. Aartsma-Rus A., Janson A.A., Kaman W.E., et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 12:2003;907-914.
87. Bertoni C., Lau C., Rando T.A. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping. Hum Mol Genet. 12:2003;1087-1099.
88. Nevo Y., Muntoni F., Sewry C., et al. Large in-frame deletions of the rod-shaped domain of the dystrophin gene resulting in severe phenotype. Isr Med Assoc J. 5:2003;94-97.
89. Bushby K.M., Gardner-Medwin D., Nicholson L.V., et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy, II: correlation of phenotype with genetic and protein abnormalities. J Neurol. 240:1993;105-112.
90. Roberts M., Dickson G. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene. Curr Opin Mol Ther. 4:2002;343-348.
91. Wells D.J., Wells K.E., Asante E.A., et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet. 4:1995;1245-1250.
92. Harper S.Q., Hauser M.A., DelloRusso C., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 8:2002;253-261.
93. Chamberlain J.S. Gene therapy of muscular dystrophy. Hum Mol Genet. 11:2002;2355-2362.
94. Roberts R.G., Gardner R.J., Bobrow M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum Mutat. 4:1994;1-11.
95. Roberts R.G., Bobrow M., Bentley D.R. Point mutations in the dystrophin gene. Proc Natl Acad Sci USA. 89:1992;2331-2335.
96. Tuffery S., Lenk U., Roberts R.G., Coubes C., Demaille J., Claustres M. Protein truncation test: analysis of two novel point mutations at the carboxy-terminus of the human dystrophin gene associated with mental retardation. Hum Mutat. 6:1995;126-135.
97. Tuffery-Giraud S., Chambert S., Demaille J., Claustres M. Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects. Hum Mutat. 14:1999;359-368.
98. Roest P.A., Roberts R.G., van der Tuijn A.C., Heikoop J.C., van Ommen G.J., den Dunnen J.T. Protein truncation test (PTT) to rapidly screen the DMD gene for translation terminating mutations. Neuromuscul Disord. 3:1993;391-394.
99. Whittock N.V., Roberts R.G., Mathew C.G., Abbs S.J. Dystrophin point mutation screening using a multiplexed protein truncation test. Genet Test. 1:1997;115-123.
100. Ferlini A., Galie N., Merlini L., Sewry C., Branzi A., Muntoni F. A novel Alu-like element rearranged in the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy. Am J Hum Genet. 63:1998;436-446.
101. Ginjaar I.B., Kneppers A.L., v d Meulen J.D., et al. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. Eur J Hum Genet. 8:2000;793-796.
102. Shiga N., Takeshima Y., Sakamoto H., et al. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest. 100:1997;2204-2210.
103. Dolinsky L.C., de Moura-Neto R.S., Falcao-Conceicao D.N. DGGE analysis as a tool to identify point mutations, de novo mutations and carriers of the dystrophin gene. Neuromuscul Disord. 12:2002;845-848.
104. Mendell J.R., Buzin C.H., Feng J., et al. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology. 57:2001;645-650.
105. Feng J., Yan J., Buzin C.H., Towbin J.A., Sommer S.S. Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy. Mol Genet Metab. 77:2002;119-126.
106. Flanigan K.M., von Niederhausern A., Dunn D.M., Alder J., Mendell J.R., Weiss R.B. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet. 72:2003;931-939.
107. Bennett R.R., den Dunnen J., O'Brien K.F., Darras B.T., Kunkel L.M. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genet. 2:2001;17.
108. Prior T.W., Bartolo C., Papp A.C., et al. Identification of a missense mutation, single base deletion and a polymorphism in the dystrophin exon 16. Hum Mol Genet. 3:1994;1173-1174.
109. Eraslan S., Kayserili H., Apak M.Y., Kirdar B. Identification of point mutations in Turkish DMD/BMD families using multiplex-single stranded conformation analysis (SSCA). Eur J Hum Genet. 7:1999;765-770.
110. Lenk U., Oexle K., Voit T., et al. A cysteine 3340 substitution in the dystroglycan-binding domain of dystrophin associated with Duchenne muscular dystrophy, mental retardation and absence of the ERG b-wave. Hum Mol Genet. 5:1996;973-975.
111. Goldberg L.R., Hausmanowa-Petrusewicz I., Fidzianska A., Duggan D.J., Steinberg L.S., Hoffman E.P. A dystrophin missense mutation showing persistence of dystrophin and dystrophin-associated proteins yet a severe phenotype. Ann Neurol. 44:1998;971-976.
112. Muntoni F., Cau M., Ganau A., et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med. 329:1993;921-925.
113. Muntoni F., Di Lenarda A., Porcu M., et al. Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy. Heart. 78:1997;608-612.
114. Ferlini A., Sewry C., Melis M.A., Mateddu A., Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord. 9:1999;339-346.
115. Bastianutto C., De Visser M., Muntoni F., Klamut H.J., Patarnello T. A novel muscle-specific enhancer identified within the deletion overlap region of two XLDC patients lacking muscle exon 1 of the human dystrophin gene. Genomics. 80:2002;614-620.
116. Milasin J., Muntoni F., Severini G.M., et al. A point mutation in the 59 splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet. 5:1996;73-79.
117. Feng J., Yan J.Y., Buzin C.H., Sommer S.S., Towbin J.A. Comprehensive mutation scanning of the dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy. J Am Coll Cardiol. 40:2002;1120-1124.
118. Yoshida K., Nakamura A., Yazaki M., Ikeda S., Takeda S. Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy. Hum Mol Genet. 7:1998;1129-1132.
119. Muntoni F., Wilson L., Marrosu G., et al. A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest. 96:1995;693-699.
120. Franz W.M., Muller M., Muller O.J., et al. Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy. Lancet. 355:2000;1781-1785.
121. Oldfors A., Eriksson B.O., Kyllerman M., Martinsson T., Wahlstrom J. Dilated cardiomyopathy and the dystrophin gene: an illustrated review. Br Heart J. 72:1994;344-348.
122. Anderson J.L., Head S.I., Rae C., Morley J.W. Brain function in Duchenne muscular dystrophy. Brain. 125:2002;4-13.
123. Mehler M.F. Brain dystrophin, neurogenetics and mental retardation. Brain Res Brain Res Rev. 32:2000;277-307.
124. Emery A.E., Muntoni F. Duchenne Muscular Dystrophy. 3rd edn:2003;Oxford University Press, Oxford.
125. Bresolin N., Castelli E., Comi G.P., et al. Cognitive impairment in Duchenne muscular dystrophy. Neuromuscul Disord. 4:1994;359-369.
126. Bushby K.M., Appleton R., Anderson L.V., Welch J.L., Kelly P., Gardner-Medwin D. Deletion status and intellectual impairment in Duchenne muscular dystrophy. Dev Med Child Neurol. 37:1995;260-269.
127. Hodgson S.V., Abbs S., Clark S., et al. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy, with special reference to mental ability. Neuromuscul Disord. 2:1992;269-276.
128. Rapaport D., Passos-Bueno M.R., Takata R.I., et al. A deletion including the brain promoter of the Duchenne muscular dystrophy gene is not associated with mental retardation. Neuromuscul Disord. 2:1992;117-120.
129. Felisari G., Martinelli Boneschi F., Bardoni A., et al. Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. Neurology. 55:2000;559-564.
130. Moizard M.P., Billard C., Toutain A., Berret F., Marmin N., Moraine C. Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy? Am J Med Genet. 80:1998;32-41.
131. Moizard M.P., Toutain A., Fournier D., et al. Severe cognitive impairment in DMD: obvious clinical indication for Dp71 isoform point mutation screening. Eur J Hum Genet. 8:2000;552-556.
132. Lenk U., Hanke R., Thiele H., Speer A. Point mutations at the carboxy terminus of the human dystrophin gene: implications for an association with mental retardation in DMD patients. Hum Mol Genet. 2:1993;1877-1881.
133. Cau M., Cao A., Loi D., et al. Two novel mutations (10410 T_G; 10296 del C) at carboxy-terminus of the dystrophin gene associated with mental retardation: mutations in brief no 149, online. Hum Mutat. 12:1998;70.
134. Melis MA, Muntoni F, Cau M, et al. Novel nonsense mutation (C_A nt 10512) in exon 72 of dystrophin gene leading to exon skipping in a patient with a mild dystrophinopathy. Hum Mutat 1998; (suppl 1): S137-38.
135. Brunig I., Suter A., Knuesel I., Luscher B., Fritschy J.M. GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABA(A) receptors and gephyrin. J Neurosci. 22:2002;4805-4813.
136. Vaillend C., Billard J.M. Facilitated CA1 hippocampal synaptic plasticity in dystrophin-deficient mice: role for GABAA receptors? Hippocampus. 12:2002;713-717.
137. Knuesel I., Mastrocola M., Zuellig R.A., Bornhauser B., Schaub M.C., Fritschy J.M. Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice). Eur J Neurosci. 11:1999;4457-4462.
138. Howard P.L., Dally G.Y., Wong M.H., et al. Localization of dystrophin isoform Dp71 to the inner limiting membrane of the retina suggests a unique functional contribution of Dp71 in the retina. Hum Mol Genet. 7:1998;1385-1391.
139. Pillers D.M., Weleber R.G., Woodward W.R., Green D.G., Chapman V.M., Ray P.N. mdxCv3 mouse is a model for electroretinography of Duchenne/Becker muscular dystrophy. Invest Ophthalmol Vis Sci. 36:1995;462-466.
140. Pillers D.M., Fitzgerald K.M., Duncan N.M., et al. Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations. Hum Genet. 105:1999;2-9.
141. Pillers D.A., Weleber R.G., Green D.G., et al. Effects of dystrophin isoforms on signal transduction through neural retina: genotype-phenotype analysis of duchenne muscular dystrophy mouse mutants. Mol Genet Metab. 66:1999;100-110.
142. Sigesmund D.A., Weleber R.G., Pillers D.A., et al. Characterization of the ocular phenotype of Duchenne and Becker muscular dystrophy. Ophthalmology. 101:1994;856-865.
143. Pascual Pascual S.I., Molano J., Pascual-Castroviejo I. Electroretinogram in Duchenne/Becker muscular dystrophy. Pediatr Neurol. 18:1998;315-320.
144. Pillers D.A., Seltzer W.K., Powell B.R., et al. Negative-configuration electroretinogram in Oregon eye disease: consistent phenotype in Xp21 deletion syndrome. Arch Ophthalmol. 111:1993;1558-1563.
145. Dalloz C., Claudepierre T., Rodius F., Mornet D., Sahel J., Rendon A. Differential distribution of the members of the dystrophin glycoprotein complex in mouse retina: effect of the mdx(3Cv) mutation. Mol Cell Neurosci. 17:2001;908-920.
146. Dalloz C., Sarig R., Fort P., et al. Targeted inactivation of dystrophin gene product Dp71: phenotypic impact in mouse retina. Hum Mol Genet. 12:2003;1543-1554.
147. Kameya S., Araki E., Katsuki M., et al. Dp260 disrupted mice revealed prolonged implicit time of the b-wave in ERG and loss of accumulation of beta-dystroglycan in the outer plexiform layer of the retina. Hum Mol Genet. 6:1997;2195-2203.
148. Girlanda P., Quartarone A., Buceti R., et al. Extra-muscle involvement in dystrophinopathies: an electroretinography and evoked potential study. J Neurol Sci. 146:1997;127-132.
149. Pillers D.A. Dystrophin and the retina. Mol Genet Metab. 68:1999;304-309.